Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090063 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
A NA study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT01090063 is a NA study that has completed, run by Tufts Medical Center. The registered enrollment target is 26 participants.
The verdict
NCT01090063, a NA study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
Interventions
- DRUG Ustekinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090063
The ClinicalTrials.gov registry entry for NCT01090063 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ustekinumab is the first listed.
NCT01090063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090063 about?
NCT01090063 is a clinical study titled "Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis". The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
What is the current status of trial NCT01090063?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2010-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01090063?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT01090063?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.